In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amphora Discovery Corp.

Latest From Amphora Discovery Corp.

Forest falls flat as Lexapro sales falter

Forest Laboratories' revenues fell flat in the third quarter of its fiscal year 2009 as sales of its lead product Lexapro declined significantly.


Investing in Hard Times

VCs worried about depressed financial markets and demanding Big Pharma customers are being tough on almost all start-ups seeking funding-but no tougher than on their existing portfolio companies. For some, hard times are creating opportunities. The circumstances of companies that raised money in the past few years are impacting newer firms now. Even organizations that met their milestones have seen valuations plummet, and are struggling to get financing. The down market is making it more desirable and easier for VCs to invest in late-stage start-ups. In-licensing has been popular, but investors are increasingly seeking value-priced components to fill out existing firms or launch new ones. Investors haven't stopped doing early-stage deals, but they're looking for firms with advantages that can reduce risk or cost, or speed a company to market. Drugmakers that used to sign big-money deals are now demanding that start-ups prove their technologies' merits through short-term, inexpensive pilot programs. Some firms aren't so pressed by hard times. VCs are promising stellar founders lots of support and time to take big risks they bet will pay off handsomely.
BioPharmaceutical Strategy

Meet the Market, As It Is: Amphora Emphasizes Risk Reduction

There are many ways start-ups can lower the risks of doing business in the current climate. Amphora's approach will likely include working for hire to cool cash burn while building relationships with skittish clients; leveraging assets that have ripened beyond the research phase; and helping customers reduce the risks they confront.
BioPharmaceutical Strategy

Chemogenomics: Serendipity on a Large Scale

To eliminate a bottle neck in target validation, pharmaceutical firms are turning to a new model known as chemogenomics, the use of small molecule drugs as probes to tease out a phenotypic response from multiple poorly-understood targets. One of the most ambitious efforts to date, Amphora Discovery Corp., a spin-out of lab-on-a-chip firm Caliper Technologies, was founded in September to build a database detailing the interactions of as many as 4000-12000 biological targets with half a million compounds.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amphora Discovery Corp.
  • Senior Management
  • Jeff Lucero Riley, VP, Fin. & Corp. Dev.
    C. Nicholas Hodge, PhD, VP, Chemistry & Tech.
    William P Janzen, Pres. & COO
  • Contact Info
  • Amphora Discovery Corp.
    Phone: (919) 287-6200
    PO Box 12169
    Research Triangle Park, NC 27709-2169